Peripheral Neuropathy Trial, Recruiting NCT07596030 Sponsor: University of Miami Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07596030
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

CIPN (Chemotherapy-Induced Peripheral Neuropathy) Group:

  • People aged 18 to 80 years
  • People who have previously been treated with platinum- or taxane-based chemotherapy
  • People who have had tingling, burning, or abnormal sensations in their hands and/or feet (like wearing invisible gloves or stockings) for at least 3 months, starting after their chemotherapy treatment
  • People whose worst nerve-related pain has been rated at least 4 out of 10 in the past week

Registry Group (comparison group with no current symptoms):

  • People aged 18 to 80 years
  • People who have previously been treated with platinum- or taxane-based chemotherapy
  • People who currently have no nerve-related symptoms as described above

Who may not be able to join:

  • People with an unstable heart condition or a known irregular heartbeat
  • People who have had head or neck cancer, or cancer that has spread to the head or neck
  • People who have recently had an ear injury or have an active skin condition at the area where the device would be placed
  • People who finished cancer treatment or surgery less than 2 months ago
  • People who have metal implants in the head or neck (for example, a cochlear implant)
  • People who have an implanted electronic device (for example, a pacemaker)
  • People with a known allergy to tape or adhesives
  • People with a history of seizures or epilepsy, a brain condition, or a defect in the skull
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marlon L Marlon, PT, PhD, University of Miami

Phone: 3052842359

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 June 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Retention Rate (taVNS Intervention Cohort); Retention Rate (Prospective Registry Cohort); Recruitment Rate (taVNS Intervention Cohort); Acceptability (taVNS Intervention Cohort); Treatment Adherence (taVNS Intervention Cohort)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov